Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jin Fu Kang with Docetaxel in NSCLC
NCT00260026Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of jinfukang in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Toxicity of Jin Fu Kang / docetaxel combination treatment. Started Nov 2004; status: completed.
02
Drugs
jinfukang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00260026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260026.